2019年 演講者

  • Marla Abodeely, PhD, Associate Director, Head, Bioassay/Immunoassay Method Development, Shire Pharmaceuticals
  • Kristin Abrams, Scientist, Amgen, Inc.
  • Gregory P. Adams, CSO, Sesen Bio
  • Prasad S. Adusumilli, MD FACS FCCP, Deputy Chief and Associate Attending, Thoracic Surgery; Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center (CTC), Memorial Sloan-Kettering Cancer Center
  • Mahiuddin Ahmed, PhD, CSO, Y-mAbs Therapeutics
  • Juan Carlos Almagro, PhD, Founder and Director, GlobalBio, Inc.
  • Eric S. Alonzo, PhD, Scientist, Process and Analytical Development, bluebird bio
  • Zhiqiang An, PhD, Professor, Chemistry, University of Texas Health Science Center at Houston
  • Marcela Araya, PhD, Principal Scientist, Group Leader, BioMedicine Design, Pfizer
  • Tara Arvedson, PhD, Director, Oncology Research, Amgen, Inc.
  • James Baker, Assoc Professor, Chemistry, University College London
  • Gurusamy Balakrishnan, PhD, Scientist, Bristol-Myers Squibb
  • Aditya Bardia, Asst Professor, Medicine, Harvard Medical School
  • Henri Bayle, PhD, Director, Molecular Biology, Research and Development, Bellicum
  • Roy Baynes, PhD, Senior Vice President, Global Clinical Development & CMO, Merck
  • Nicola Beaucamp, PhD, Head, Process Research, Roche Innovation Center Munich
  • Alain Beck, PhD, Senior Director, Biologics CMC and Developability, Pierre Fabre Laboratories
  • John Bell, Professor, Medicine & Biochemistry, Microbiology & Immunology, Ottawa Hospital Research Institute, University of Ottawa
  • Itai Benhar, PhD, Professor, Molecular Cell Biology and Biotechnology, Tel-Aviv University
  • William E. Bentley, PhD, Robert E. Fischell Distinguished Chair, Chemical and Biomolecular Engineering, University of Maryland, College Park
  • Chantale Bernatchez, PhD, Assistant Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, MD Anderson
  • Carl Uli Bialucha, Director, Oncology Biotherapeutics, Novartis Institutes for Biomedical Research
  • Roslyn M. Bill, DPhil, Professor, Biotechnology; Associate Dean, Research, Aston University
  • Philippe Billiald, PharmD, PhD, Professor, Biochemistry, University Paris-Sud & Acticor Biotech
  • Ruben Boado, Vice President, R&D and Co-Founder, ArmaGen, Inc.
  • Kristin Boggio, PhD, Senior Scientist, Protein Mass Spectrometry, Pfizer
  • Björn Boll, PhD, Head, Particle Lab and Higher Order Structure Protein Analytics, Novartis Pharma AG
  • Bjoern Boll, PhD, Head, Particle Lab and Higher Order Structure Protein Analytics, Novartis
  • Bettina Bommarius, PhD, Senior Research Scientist, Chemical and Biomolecular Engineering, Georgia Institute of Technology
  • Gadi Bornstein, PhD, Senior Director, Biologics Discovery, TESARO, Inc.
  • Martin Jack Borrok, PhD, Scientist II, MedImmune
  • Adrian Bot, PhD, Vice President, Translational Sciences, Kite Pharma
  • Rama Boyanapalli, PhD, Associate Director, Bioanalytical and Biomarker Development, Wave Life Sciences
  • Andrew R.M. Bradbury, MB BS, PhD, CSO, Specifica, Inc.
  • David Bramhill, PhD, Founder, Bramhill Biological Consulting, LLC
  • Caroline J. Breitbach, Vice President, R&D Programs and Strategy, Turnstone Biologics
  • Jo Brewer, PhD, Vice President, Platform Sciences, Adaptimmune
  • Zachary T. Britton, PhD, Scientist, Antibody Discovery and Protein Engineering, MedImmune, LLC
  • Julie Brouchon, PhD, Postdoctoral Associate, Weitz Lab, Harvard University
  • Kristin Brown, PhD, Director, Protein Design and Informatics, GlaxoSmithKline
  • Johannes Brozy, PhD, Senior Associate Scientist, BiTE® Technology, Amgen Research (Munich) GmbH
  • Pierre Bruhns, PhD, Professor, Antibodies in Therapy & Pathology, Pasteur Institute
  • Elizabeth Brunk, PhD, Postdoctoral Research Fellow, Systems Biology Research Group, University of California, San Diego
  • Dexiu Bu, MD, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis Institute for Biomedical Research
  • Elizabeth Budde, MD, PhD, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
  • Richard Buick, PhD, CTO, Fusion Antibodies plc
  • Nicola Burgess-Brown, PhD, Principal Investigator, Biotechnology, Structural Genomics Consortium, University of Oxford
  • Noel J. Byrne, MSc, Associate Principal Scientist and Lead, Expression Group, Target Protein Design, Merck Research Laboratories
  • Iain D. G. Campuzano, Principal Scientist, Discovery Attribute Sciences, Amgen
  • Qing Chai, PhD, Principal Research Scientist, Protein BioSciences, Eli Lilly & Co.
  • John Champagne, Senior Applications Scientist\Northeast Regional Manager, Wyatt Technology
  • Brian Champion, CSO, PsiOxus Therapeutics
  • Christine P. Chan, PhD, Principal Scientist, Global Manufacturing Science & Technology, Sanofi
  • Gaurav Chauhan, MS, Associate Principal Scientist, BioProcess Development, Merck & Co., Inc.
  • Rober Chen, Assoc Professor, Hematology & Hematopietic Cell Transplantation, City of Hope National Medical Center
  • Daniel Chen, MD, PhD, CMO, IGM Biosciences
  • Anu Cherukuri, PhD, Associate Director, Immunogenicity Assessment, BioMarin Pharmaceutical
  • Yongku Cho, PhD, Assistant Professor, Chemical and Biomolecular Engineering, University of Connecticut
  • Patricia Clark, PhD, John Cardinal O’Hara, C.S.C. Professor, Chemistry & Biochemistry, University of Notre Dame
  • Adrienne Clements Egan, PhD, Scientific Director, Janssen Biotherapeutics, Janssen
  • Jennifer R. Cochran, PhD, Shriram Chair of Bioengineering; Professor of Bioengineering, and (by courtesy) Chemical Engineering, Stanford University
  • Peter Cohen, PhD, Professor, Medicine and Immunology, Mayo
  • Frank Comer, PhD, Senior Scientist, MedImmune
  • Christopher Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada
  • Timothy Cripe, Professor and Chief, Division of Hem/Onc/BMT, Nationwide Children's Hospital
  • Conrad Russell Cruz, PhD, Director, Translational Research Laboratories, Center for Emerging Technologies in Immune Cell Therapy, Children's National Health System
  • Michael Curran, PhD, Associate Professor, Department of Immunology, MD
  • Brendan Curti, PhD, Robert W. Franz Chair for Clinical Research, Earle A. Chiles Research Institute, Providence
  • Katherine Cygnar, Senior Staff Scientist, Genome Engineering Technologies, Regeneron Pharmaceuticals
  • Abhishek Datta, PhD, Director, Antibody Discovery & Engineering, Scholar Rock
  • Naval G. Daver, MD, Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center
  • Claire Davies, Assoc Vice President, Bioanalytics, Sanofi
  • Charlotte Deane, PhD, Professor of Structural Bioinformatics & Head of Department, Department of Statistics University of Oxford; Head of the Oxford Protein Informatics Group, University of Oxford
  • Stephanie Dearmey, MD, Pediatrician, Pediatrics, Medical Genetics, Duke University Medical Ctr
  • Gaël Debauve, PhD, Head, Bioassay Development, Analytical Sciences for Biologics, UCB
  • Shara Dellatore, PhD, Director, Regulated Immunogenicity and Molecular Biology Bioanalytics, Merck and Co
  • Mark Dennis, PhD, Fellow, Denali Therapeutics
  • Vijay Dhawan, PhD, Associate Director, Analytical Development, Sanofi
  • Iulia Diaconu, PhD, Associate Director, Immunotherapy, Bluebird
  • Alan Dickson, PhD, Professor, Biotechnology; Director, Centre of Excellence in Biopharmaceuticals (COEBP), University of Manchester
  • Gundo Diedrich, PhD, Director, Antibody Engineering, MacroGenics
  • Antonio DiGiandomenico, PhD, Principal Scientist, Microbial Sciences, MedImmune
  • Nazzareno Dimasi, Assoc Director, R&D, MedImmune
  • Rakesh Dixit, PhD, Vice President of R&D & Global Head  of Translational Sciences-Biologics Safety Assessment, MedImmune
  • Zhandong Don Zhong, PhD, Associate Director, Specialty Bioanalytics, Teva
  • Benjamin Doranz, President and CEO, Integral Molecular
  • Susan Dounce, PhD, Principal SME, Prefilled Syringes, West Pharmaceutical Services
  • Zhimei Du, PhD, Director, Bioprocess, Merck & Company, Inc.
  • Franck Duong, PhD, Professor and Principal Investigator, Biochemistry & Molecular Biology, University of British Columbia
  • David Eavarone, PhD, Associate Principal Scientist, Harbour Biomed
  • Samuel Ellis, Vice President, Thomson Instrument Company
  • Peter Ellmark, PhD, Vice President, Discovery, Alligator
  • Christine E. Engeland, MD, PhD, Head of Laboratory, Virotherapy, National Center for Tumor Diseases
  • Alan Epstein, Professor, Keck School of Medicine, University of Southern California
  • Patrik Erlmann, Head, R&D, ViraTherapeutics GmbH
  • Ugur Eskiocak, PhD, Associate Director, Translational Immunology & Immunopharmacology, Compass Therapeutics
  • Abbie Esterman, PhD, Senior Scientist, Methods and Analytical Development,
  • Bristol-Myers Squibb
  • Tarek Fahmy, PhD, Associate Professor, Biomedical Engineering and Immunobiology, Yale University
  • Jessy Fan, PhD, Scientist, Amgen
  • Maria Fardis, PhD, CEO, Iovance
  • Denise Faustman, PhD, Director of Immunobiology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard
  • Fortunato Ferrara, PhD, Vice President, Specifica, Inc.
  • Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital
  • Deborah Finco, PhD, President, Deborah Finco Consulting LLC, consultant
  • Simon Fischer, PhD, Head, Cell Line Development, Global Bioprocess & Pharmaceutical Development, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Anna Fogdell Hahn, PhD, Associate Professor, Clinical Neuroscience, Clinical Neuroimmunology, Karolinska University Hospital, Sweden
  • Daron Forman, PhD, Principal Scientist, Molecular Discovery Technologies, BMS
  • Fredrik Frejd, CSO, Affibody AB
  • Masha Fridkis-Hareli, MSc, PhD, Founder and President, ATR, LLC
  • Simon Friedensohn, MSc, Research Assistant, Biosystems Science and Engineering, ETH Zurich
  • Richard Galas, PhD, Senior Scientist, Takeda
  • Leena Gandhi, MD, PhD, Vice President, Immuno-Oncology Medical Development, Lilly Oncology
  • Rajkumar Ganesan, PhD, Director, Antibody Engineering, Janssen Biotherapeutics
  • Sandra Garces, MD, PhD, Senior Medical Advisor for Immunogenicity, GPS Medical and Benefit-Risk Management, Lilly
  • Narender Gavva, Director, Early Target Discovery, Takeda
  • Gerald Gellermann, PhD, Senior Fellow, Novartis
  • Nimish Gera, PhD, Director, Research and Development, Mythic Therapeutics
  • C. Ronald Geyer, PhD, Professor, Pathology and Lab Medicine, University of Saskatchewan
  • Sharareh Gholamin, MD, PhD Candidate, Department of Biology and Biological Engineering, California Institute of Technology
  • Raja Ghosh, PhD, Professor, Chemical Engineering, McMaster University
  • Theo Giavridis, PhD, Center for Cell Engineering, MSK
  • David Gilham, PhD, Vice President, Research, Celyad
  • William Gillette, PhD, Principal Scientist, RAS Reagents Core; Deputy Director, Protein Expression Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research (FNL)
  • Jacob G. Glanville, Co-Founder & CSO, Distributed Bio Inc.
  • Benjamin Glick, PhD, Professor, Molecular Genetics and Cell Biology, University of Chicago
  • Sayed Goda, Professor & Senior Scientist, Anti-Doping Lab Qatar, Cairo University
  • Theresa Goletz, PhD, Global Head, NBE Drug Disposition, EMD serono
  • María González Pajuelo, CSO, FairJourney Biologics
  • Ulrich Göpfert, PhD, Principal Scientist, Cell Line & Molecular Development, Roche Innovation Center Munich
  • Bharathi Govindarajan, PhD, Senior Scientist, Bioassay Development, ImmunoGen, Inc.
  • Christilyn Graff, PhD, Director, Antibody Discovery and Engineering, Biogen
  • Paola Grandi, CSO, Cold Genesys
  • Torbjörn Gräslund, Professor, Protein Science, KTH Royal Institute of Technology
  • Jonas Heilskov Graversen, Assoc Professor, Molecular Medicine, University of Southern Denmark
  • Christopher H. Gray, PhD, Staff Scientist & Team Leader, Structural Biology, Drug Discovery Program, CRUK Beatson Institute
  • James L. Gulley, MD, PhD, FACP, Chief or Genitourinary Malignancies Branch, & Director of Medical Oncology Service, Center for Cancer Research, NCI
  • Soumi Gupta, PhD, Director, Immunogenicity Assessment, BioMarin Pharmaceutical Inc., Biomarin
  • Claes Gustafsson, Build Better Biologics with Machine Learning and Synbio, ATUM (formerly DNA2.0)
  • Markus Haberger, PhD, Senior Scientist, Roche
  • Graeme Hacking, Medical Director, Amgen, Inc.
  • William Hallett, PhD, Biologist, OPQ/OBP, CDER, FDA
  • Jeffrey Harris, Assoc Director, Translational Research, Genmab
  • Haruki Hasegawa, PhD, Principal Scientist, Biologics – Protein Technology, Amgen, Inc.
  • Raffit Hassan, MD, Senior Investigator & Chief, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH
  • Kathryn Hastie, PhD, Staff Scientist, Immunology and Microbiology, The Scripps Research Institute
  • Thomas Held, Vice President, ADC Task Force, Daiichi Sankyo
  • Prof. Dr. Helfrich, WijnandProfessor of Translational Surgical Oncology, Department of Surgery, University Medical Center Groningen
  • Ronald Herbst, PhD, Vice President and Head, Oncology Research, MedImmune
  • Guy Hermans, CSO, Isogenica Ltd
  • Tim Hickling, PhD, Immunogenicity Sciences Lead, Biomedicine Design, Pfizer
  • Stuart Hicks, Assoc Director, Pipeline R&D, ImmunoGen
  • Oliver Hill, Vice President, Molecular Biology/Protein Engineering, Drug Discovery, Apogenix AG
  • MaryJane Hinrichs, Clinical Scientist, Assoc Director, MedImmune
  • Mitchell Ho, PhD, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, NCI, NIH
  • F. Stephen Hodi, MD, Professor & Sharon Crowley Martin Chair,  Harvard Medical School, Dana-Farber Cancer Institute
  • Rene Hoet, PhD, Head, Antibody Lead Discovery, Bayer AG
  • Per Sonne Holm, Head, Virotherapy Research Group, Urology, Technical University Munich
  • Damian Houde, PhD, Associate Director, Process Analytics, Codiak BioSciences
  • Jeffrey A. Hubbell, Eugene Belle Professor, Tissue Engineering, Institute for Molecular Engineering, University of Chicago
  • Michael Hudecek, PhD, Program Leader, Max Eder Research Group‚ CAR T-Cell Engineering, Department of Medicine II, Uni of Wurzburg
  • Greta Hultqvist, PhD, Associate Senior Lecturer, Pharmaceutical Biosciences, Protein Drug Design,
  • Duncan Huston-Paterson, Product Manager, Integral Molecular
  • Catherine Hutchings, PhD, Independent Consultant,
  • Robert Iannone, Head, R&D, CMO, Immunomedics
  • Antonio Iglesias, PhD, Expert Scientist, Pharma Research and Early Development, Roche
  • Gregory C. Ippolito, PhD, Research Assistant Professor, Molecular Biosciences, LIVESTRONG Cancer Institute, The University of Texas at Austin
  • Juan Jaen, PhD, President, Arcus Bioscience
  • Anika Jäkel, PhD, Director, Preclinical Pharmacology & Cancer Immunology, Glycotope GmbH
  • Darshana Jani, MSc, Associate Director, Global Lead Biologics, Clinical Assay Group, Global Product Development, Pfizer, Inc.
  • Darshana Jani, PhD, Associate Director & Global Lead Biologics, Pfizer Inc, Pfizer
  • Vibha Jawa, PhD, Director and Lead, Predictive and Clinical Immunogenicity, Merck
  • Moonsoo M. Jin, PhD, Associate Professor, Molecular Imaging Innovations Institute, Radiology, Weill Cornell Medical College
  • Matt Johnson, CSO, Avacta Life Sciences
  • Sujith K. Joseph, PhD, Scientist, Pediatrics Hematology-Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine
  • Michelle Joubert, Scientist, Analytical Development, Sanofi
  • Jean-Philippe Julien, PhD, Canada Research Chair in Structural Immunology, The Hospital for Sick Children Research Institute
  • Meelis Kadaja, PhD, MBA, Director of Business Development, Icosagen Cell Factory
  • John Kamerud, PhD, Director, Bioanalytical, Pfizer
  • Denise Karaoglu Hanzatian, PhD, Principal Research Scientist, Biologics Discovery, AbbVie Bioresearch Center, AbbVie
  • David Karig, PhD, Associate Professor, Systems and Synthetic Biology, Bioengineering, Clemson University
  • Dennis Karthaus, MSc, IBA Lifesciences
  • Brian K. Kay, PhD, Professor &  Head, Biological Sciences, University of Illinois, Chicago
  • Alex Kelly, US Business Development Manager, Retrogenix Limited
  • Ryan Kelly, PhD, Research Scientist, xCella Biosciences
  • Saad Kenderian, PhD, Assistant Professor, Medicine and Oncology, Mayo
  • Robert Kernstock, PhD, Senior Group Leader, R&D, Immunochemistry, PPDI
  • Jennifer Kessler, Senior Development Associate, MacroGenics, Inc.
  • Bruce Keyt, PhD, CSO, IGM Biosciences
  • Tarik Khan, PhD, Senior Scientist, Late-Stage Pharmaceutical and Processing Development, F. Hoffmann-La Roche Ltd.
  • Philip M. Kim, PhD, Associate Professor, The Donnelly Centre for Cellular and Biomolecular Research, Departments of Molecular Genetics and Computer Science, University of Toronto
  • Yong Sung Kim, PhD, Professor, Molecular Science & Technology, Ajou University
  • Kei Kishimoto, CSO, Selecta Biosciences
  • Scott L. Klakamp, PhD, Senior Director & Head, Biophysics, Biologics Development Sciences, Janssen BioTherapeutics
  • Christian Klein, PhD, Oncology Discovery & Translational Area, Cancer Immunotherapy Discovery, PRED, Roche Innovation Center, Zurich
  • Hans Klingemann, PhD, Vice President, Research and Development, Nantkwest
  • Emilee Knowlton, Immunology Sales Specialist, ProImmune Inc.
  • Luke Koblan, PhD, Scientist, Chemical Biology, Chemistry & Chemical Biology, Harvard University
  • Sergii Kolodych, CSO, Syndivia
  • Roland Kontermann, PhD, Professor of Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart
  • Natalia Kozhemyakina, PhD, Head, Bioassay Laboratory, Analytical Development Department, BIOCAD
  • Serguei Kozlov, Principal Scientist/PM, Team Leader PTO, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research (NCI)
  • Daniel Kramer, PhD, Global Scientific Advisor Clinical Immunogenicity, Sanofi, Munich Center
  • Michael Krogh Jensen, PhD, Senior Researcher & Co-Principal Investigator, Technical University of Denmark, Novo Nordisk Foundation Center for Biosustainability
  • Andreas Kungl, CEO, Antagonis Biotherapeutics GmbH
  • Christian Kunz, PhD, Director, MorphoSys AG
  • Jonathan R. Lai, PhD, Professor, Department of Biochemistry, Albert Einstein College of Medicine
  • Martine LM Lamfers, Assoc Professor, Neurosurgery, Brain Tumor Center, Erasmus Medical Center
  • David Lansky, PhD, President, Precision Bioassay, Inc.
  • Laurent Larivière, PhD, Head, Mass Spectrometry, Large Molecule Research, Roche Innovation Center Munich
  • Holger Laux, PhD, Fellow, Cell Line Development, Novartis Institutes for BioMedical Research
  • Sean Lawler, Asst Professor, Managing Director, Harvey Cushing Neurosurgery Laboratories, Brigham and Women's Hospital
  • Robert J. Lechleider, Senior Vice President, Clinical Research, Seattle Genetics
  • Sun Bae Lee, Senior Research Scientist, Alteogen
  • James Legg, PhD, Vice President, Research and Development, Crescendo Biologics
  • Hans-Georg Lerchen, Chief Scientist, R&D Pharmaceuticals, Bayer AG
  • Zonghai Li, PhD, CEO and CSO, CARSgen
  • John Liddell, PhD, Senior Scientific Advisor, National Biologics Manufacturing Centre, Centre for Process Innovation
  • Thomas Little, PhD, President and CEO, Bioassay Sciences, Thomas A. Little Consulting
  • David V. Liu, Director, Protein Engineering, Abbvie
  • Liming Liu, PhD, Senior Principal Scientist, Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM), Merck Research Laboratories
  • Deryk Loo, PhD, Director, Targeted Therapeutics and Site Operations, MacroGenics, Inc.
  • James Love, PhD, Chief Operating Officer, Institute for Protein Innovation
  • Emily Lowe, PhD, Senior Scientist, Analytical Sciences, Kite Pharma, a Gilead Company
  • Eline T. Luning Prak, MD, PhD, Associate Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
  • Patrick Lupardus, PhD, Senior Scientist and Group Leader, Genentech
  • Robert Lutz, Principal Consultant, Crescendo Biopharma Consulting
  • Andrew Lynch, Scientific Consultant, Genedata
  • Robert Mabry, PhD, Lead, Biologics Research Group, Takeda
  • Loui Madakamutil, PhD, Vice President, Head of Discovery, Nektar
  • Sheila G. Magil, PhD, Principal Consultant, BioProcess Technology Consultants, Inc.
  • Maksim Mamonkin, PhD, Assistant Professor, Center for Cell and Gene Therapy, BCM
  • John R. Mascola, MD, Director, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH
  • Yariv S. Mazor, PhD, Senior Scientist, Antibody Discovery & Protein Engineering, MedImmune
  • Charlotte McDonagh, Vice President, Head of Biotherapeutics, Magenta Therapeutics
  • Kathleen McGuiness, PhD, Senior Director, Platform Technologies, Unum Therapeutics
  • Sarah McWhirter, PhD, Director, STING Research, Aduro
  • Sebastian Meyer, COO, Numab Innovation AG
  • Shahram Misaghi, PhD, Senior Scientist, Early Stage Cell Culture, Genentech, Inc.
  • Alexey Misorin, Senior Research Associate, Antibody Discovery, BIOCAD
  • Arturo Molina, CMO, Sutro Biopharma Inc.
  • Céline Monnet, Head of Laboratory, Research, LFB Biotechnologies
  • Hatim Motiwala, PhD, Head, Cell Line Engineering and Bio-Analytical Sciences, Enzene Biosciences Limited
  • Liviu Movileanu, PhD, Professor, Physics, Syracuse University
  • Ashley Mullan, Scientist, Development, Analytical Sciences, MedImmune
  • Smita Nair, Professor, Surgery, Neurosurgery and Pathology, Duke University School of Medicine
  • Dhaval Nanavati, PhD, Senior Scientist, AbbVie
  • Brent Nannenga, PhD, Assistant Professor, Chemical Engineering, Arizona State University
  • Horacio G. Nastri, PhD, Senior Director, Antibody Biotherapeutics, Incyte Corporation
  • Brad Nelson, PhD, Co-Director, Immunotherapy Program, British Columbia Agency
  • Jennifer F. Nemeth, PhD, SCPM, Director, Biophysics, Structural Characterization, Biologics Discovery Sciences, Janssen Research & Development
  • Dario Neri, Professor, Chemistry & Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich)
  • Anton Neschadim, CEO, ImmunoBiochem Corporation
  • Chris Neumann, Principal Scientist, Medicinal Chemistry, Seattle Genetics
  • Ahuva Nissim, PhD, Professor, Antibody and Therapeutic Engineering, Biochemical Pharmacology, Queen Mary University
  • Tatiana Novobrantseva, PhD, Co-Founder, Head of Research and Development, Verseau Therapeutics
  • Mark O’Hara, MD, GI Malignancy Oncologist, University of Pennsylvania
  • Maureen O'Connor-McCourt, CSO, Forbius
  • Martin Oft , PhD, Senior Vice President, Preclinical and Clinical R&D, ArmoBio
  • Shimobi Onuoha , PhD, Head, Protein Engineering, Autolus
  • Ira H. Pastan, MD, Co-Chief, Laboratory of Molecular Biology; NIH Distinguished Investigator; Head, Molecular Biology Section, NIH
  • Belinda Pastrana, Chief Executive Officer, Protein Dynamic Solutions
  • Li Peng, PhD, Vice President, Biotherapeutics Discovery, Palleon Pharmaceuticals
  • Thomas Pillow, Senior Scientist, Discovery Chemistry, Genentech, Inc.
  • Renuka Pillutla, PhD, Executive Director, Lead, Bioanalytical Sciences, BMS
  • Guy Poirier, PhD, Professor, Faculty of Medicine, Scientific Advisor, Proteomics Platform CHU of Quebec, Université Laval
  • Tony Polverino, PhD, Executive Vice President of Early Development & CSO, Zymeworks Inc.
  • Francis Poulin, Director, Analytical Development, Sanofi
  • Daniel Powell, PhD, Associate Professor of Pathology and Laboratory Medicine, Penn
  • Ken Prentice, Senior Scientist, Biochemistry, Juno Therapeutics
  • Nuša Pristovšek, PhD, Postdoctoral Researcher, The Novo Nordisk Foundation Center for Biosustainability (CFB), Technical University of Denmark
  • Jack Ragheb, MD, PhD, Co-Chair, Immunogenicity/Immunosafety Working Group, Senior Medical Fellow for Immunogenicity, Global Patient Safety, Lilly
  • Ronald T. Raines, PhD, Firmenich Professor of Chemistry, Department of Chemistry, Massachusetts Institute of Technology
  • G. Jonah Rainey, PhD, CEO, Oriole Biotech, Inc.
  • Jonah Rainey, PhD, Vice President, Antibody Therapeutics, Gritstone
  • Romesh Rao, Research Associate, Analytical Sciences, Seattle Genetics
  • Harun Rashid, Senior Principal Scientist, Molecular Technology, Ambrx
  • Harun Rashid, PhD, Senior Principal Scientist, Molecular Technology, Ambrx, Inc.
  • Andreas Raue, PhD, Associate Director, Research, Merrimack
  • Jeffrey V. Ravetch, MD, PhD, Theresa and Eugene M. Lang Professor, Immunology, Virology, and Microbiology, Rockefeller University
  • Sai Reddy, PhD, Assistant Professor, Biosystems Science and Engineering, ETH Zurich
  • Will Redmond, PhD, Associate Member, Laboratory of Cancer Immunotherapy, Director, Immune Monitoring Laboratory, Providence
  • Susan Richards, PhD, Presidential Scientific Fellow, Translational Medicine Early Development, Sanofi
  • Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine, Harvard Medical School
  • Frank J. Riske, PhD, Senior Consultant, BioProcess Technology Consultants, Inc.
  • Theo Rispen, PhD, Principle Investigator, Antibody Structure and Function, Sanquin
  • Mark Rixon, Senior Director, Protein Therapeutics, Alpine Immune Services
  • Marc-André Robert, PhD, Scientist, Technology Development, BioMarin Pharmaceuticals
  • David D. Roberts, PhD, Senior Investigator, Head, Biochemical Pathology Section, Laboratory of Pathology, CCR, NCI, NIH
  • Kevin Roberts, PhD, Senior Scientist and Project Leader, Vhsquared
  • Gabriel Rocklin, PhD, Assistant Professor, Department of Pharmacology & Center for Synthetic Biology, Northwestern University
  • Theo Roth, PhD, Department of Microbiology and Immunology, UCLA
  • Gargi Roy, MSc, Scientist, Antibody Discovery and Protein Engineering, MedImmune, LLC
  • Marco Ruella, PhD, Clinical Instructor, Associate Director, Dr. June’s Laboratory, Center for Cellular Immunotherapies, Perelman School of Medicine, Penn
  • Brandon Ruotolo, PhD, Professor, Chemistry, University of Michigan
  • Stephen J. Russell, CEO, Vyriad Inc.
  • Charlotte Russell, MD, PhD, CMO, Alligator Bioscience AB
  • Josiah Ryman T., PhD, Senior Scientist, Predictive and Clinical Immunogenicity, Merck
  • Clifford William Sachs, PhD, Director, Research and Development, Toxicology, MedImmune
  • Jochen Salfeld, PhD, Vice President, Global Biologics; Distinguished Research Fellow, AbbVie
  • Markku Saloheimo, PhD, Senior Principal Scientist, Industrial Biotechnology and Food Solutions, VTT Technical Research Centre of Finland, Ltd.
  • Lobelia Samavati, MD, Associate Professor of Medicine, Department of Medicine, Center for Molecular Medicine and Genetics, Wayne State University School of Medicine
  • Hardeep S. Samra, PhD, Senior Director, Head, Regulatory Operations, Orphan Drug Unit, IQVIA
  • Kristi Sarno, Senior Director Business Development, Pfenex
  • Barbra Sasu, PhD, CSO, Allogene
  • Aaron Sato, Chief Scientific Officer, Twist Bioscience
  • Andreas Schaaf, PhD, Chief Scientific Officer, Greenovation Biotech GmbH
  • Jonas V. Schaefer, PhD, Lab Head/Investigator II, Novartis Institutes for BioMedical Research (NIBR)
  • Stefan Scherer, PhD, Senior Vice President, Clinical Development and Deputy CMO, Cellectis
  • Taylor Schreiber, PhD, CSO, Research & Development, Shattuck Labs
  • Jane Seagal, PhD, Principal Research Scientist, Global Biologics, AbbVie
  • Rachana Shah, Investigator, Drug Design and Selection, GlaxoSmithKline
  • Lu Shan, Scientist, Antibody Discovery & Protein Engineering, MedImmune
  • Susan Sharfstein, PhD, Professor, Nanobioscience, Nanoscale Science and Engineering, SUNY Polytechnic Institute
  • Vaneet K. Sharma, PhD, Manager, Analytical Development, Vaccine Development & Manufacturing, International AIDS Vaccine Initiative (IAVI)
  • Joseph Shiloach, PhD, Director, Biotechnology Core Lab, NIDDK, NIH
  • Anthony Shock, PhD, Director, Immunology Research, UCB
  • Sheila K. Singh, MD, PhD FRCS(C), Director or McMaster Surgeon Scientist Program & Professor of Surgery, McMaster University
  • Anupam Singhal, The Beacon™ Platform for the Rapid Discovery of Rare Antibodies to Difficult Targets, Berkeley Ligts, Inc.
  • Michael J. Smanski, PhD, Assistant Professor, Biochemistry, Molecular Biology & Biophysics, Biotechnology Institute, University of Minnesota
  • Christopher Smith, Head of Biologics, US, Genedata
  • Eric Smith, PhD, Director, Bispecifics, Regeneron Pharmaceuticals
  • Perceval Sondag, Senior Manager, Statistics, PharmaLex
  • Paul M. Sondel, MD, PhD, Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics, and Director of Research, UW Division of Pediatric Hematology, Oncology and BMT, UW Carbone Cancer Center and American Family Children’s Hospital, University of Wisconsin
  • An Song, PhD, Senior Vice President, Development Sciences, Immune-Onc Therapeutics, Inc.
  • Christoph Spiess, PhD, Senior Scientist, Antibody Engineering, Genentech
  • Philipp Spycher, PSI Founder Fellow, Center for Radiopharmaceutical Studies (CRS), Paul Scherrer Institute
  • Kuldip Sra, PhD, Director, QC, Kite Pharma, Inc.
  • Martin Steegmaier, PhD, Head of Discovery, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich
  • Keri A. Streby, Pediatric Oncologist, Hematology & Oncology, Nationwide Children's Hospital
  • Robert M. Stroud, PhD, Professor, Biochemistry and Biophysics, Pharmaceutical Chemistry, Macromolecular Structure Group (MSG), University of California, San Francisco (UCSF)
  • Kay-Gunnar Stubenrauch, PhD, Expert Scientist, Large Molecule Bioanalytical R&D, Roche
  • Christopher Sucato, Senior Scientist, Charles River
  • Chaitanya Sudrik, PhD, Postdoctoral Associate, Molecular Engineering, Massachusetts Institute of Technology
  • Traian Sulea, PhD, Senior Research Officer, Human Health Therapeutics, National Research Council Canada
  • Sabine Suppmann, PhD, Head, Recombinant Protein Production, Max Planck Institute for Biochemistry
  • Philip Tagari, PhD, Vice President, Research, Amgen
  • Yuichiro Takagi, PhD, Associate Professor, Department of Biochemistry and Molecular Biology, Indiana University School of Medicine
  • Hiroyuki Takeda, PhD, Associate Professor and Principal Investigator, Division of Protea-Drug-Discovery Sciences, Proteo-Science Center, Ehime University
  • Rastislav Tamaskovic, Head, TC Facility, Biochemistry, University of Zurich
  • Magdalena Tary-Lehmann, MD, PhD, CSO, Cellular Technology Limited (CTL) & Adjunct Associate Professor of Pathology, Case Western Reserve University (CWRU)
  • Ali Tavassoli, PhD, Professor, Chemical Biology, University of Southampton
  • Ronen Tchelet, VP R&D, Dyadic International Inc.,
  • Grzegorz Terszowski, PhD, Lab Head, PK/PD Bioanalytics Drug Metabolism and Pharmacokinetics Biologics, Novartis
  • Christopher Thanos, PhD, CEO, Actym Therapeutics
  • Holger Thie, PhD, Senior Manager, Technology and Innovation, Biologics Development, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Greg M. Thurber, Asst Professor, Chemical Engineering and Biomedical Engineering, University of Michigan
  • John Timmer, Vice President, Research, Inhibrx
  • Sophie Tourdot, PhD, Senior Principal Scientist, Pfizer
  • Mark Trautwein, PhD, Senior Scientist, Pharmaceuticals R&D, Preclinical Research, Expression Technologies, Bayer AG
  • Mihriban Tuna, PhD, Vice President, Drug Discovery, F Star
  • Thomas Tuxen Poulsen, PhD, Principal Scientist, Preclinical Development, Symphogen A/S
  • Bob Vakamehr, PhD, Chief Development Officer, Fate
  • Daniel A. Vallera, PhD, Lion Scholar and Professor, Director, Section on Molecular Cancer Therapeutics; Professor of Therapeutic Radiology, University of Minnesota Masonic Cancer Center
  • Wilfred A. van der Donk, PhD, Richard E. Heckert Endowed Chair in Chemistry, Director of Graduate Studies, and Howard Hughes Medical Institute Investigator, Department of Chemistry, University of Illinois
  • Anne Verhagen, Director, Protein Biochemistry, CSL Research, CSL Ltd.
  • Daniela Verthelyi, MD, PhD, Chief, Immunology Lab, Therapeutic Proteins, CDER, FDA
  • Kurella Vinodh, PhD, Principal Scientist, Protein Engineering, Merrimack Pharmaceuticals
  • Bjørn Voldborg, MSc, Director, CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark
  • Eric Wakshull, PhD, Principal Scientist, Group Leader, Bioanalytical Sciences, Genentech
  • Steven Walfish, MBA, Principal Scientific Liaison, USP
  • Jihong Wang, PhD, Principal Scientist, MedImmune
  • Lintao Wang, PhD, Associate Director, Analytical and Pharmaceutical Development, ImmunoGen, Inc.
  • Stacy Ward Ward, PhD, Senior R&D Scientist, Cell Design Studio, MilliporeSigma, MilliporeSigma
  • Gregory A. Weiss, PhD, Professor, Chemistry, Molecular Biology & Biochemistry, University of California, Irvine
  • Ron Weiss, PhD, Professor, Biological Engineering, Massachusetts Institute of Technology (MIT)
  • Duane R. Wesemann, MD, PhD, Principal Investigator, Assistant Professor of Medicine, Harvard Medical School & Associate Physician, Brigham and Women’s Hospital
  • Tim Whitehead, PhD, Associate Professor, Chemical and Biological Engineering, University of Colorado, Boulder
  • Sajith Wickramasekara, CEO and Co-Founder, Benchling
  • Ian Wilkinson, Chief Scientific Officer, Absolute Antibody, Ltd.
  • Erin Williams, Associate Lab Head of Quality Control, EMD Serono
  • Pierre Wils, PhD, Head, Biologics Formulation and Process Development, Sanofi
  • Patrick C. Wilson, PhD, Professor, Medicine & Rheumatology, Knapp Center for Lupus and Immunology Research, Committee on Immunology, University of Chicago
  • K. Dane Wittrup, PhD, C.P. Dubbs Professor, Chemical Engineering and Biological Engineering; Associate Director, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
  • Liliana Wroblewska, PhD, Principal Scientist, Biomedicine Design, Pfizer, Inc.
  • Wen Jin Wu, Senior Investigator, OBP, CDER, Food & Drug Administration
  • Mingjie Xie, CEO, Rapid Novor, Inc.
  • Ryan Yamagata, US Function Head, CMC Statistical Sciences, Vaccines Technical Research & Development, GSK
  • Xiaodong Yan, Executive Director, Biortus Biosciences Co., Ltd.
  • Harry Yang, PhD, Senior Director, Statistical Sciences, Medimmune, LLC
  • Travis Young, PhD, Vice President, Biologics, CALIBR
  • Mimi Cho Yung, PhD, Staff Scientist, Biosciences and Biotechnology Division, Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory (LLNL)
  • Alexandra (Sasha) Zaitsev, Development Associate, Analytical & Pharmaceutical Sciences, ImmunoGen
  • Baochun Zhang, PhD, Assistant Professor of Medicine, Department of Medical Oncology, Dana Faber
  • Shuli Zhang, PhD, Principal Scientist, PPDM Global Bioanalytics, Merck and Co.
  • Jane Zhao, PhD, Principal Scientist, Immunogen
  • Qing (Joanna) Zhou, PhD, Product Quality Team Leader, Division of Biotechnology Review and Research I (DBRR I), OBP, CDER, FDA
  • Li Zhou, PhD, Senior Scientist, Global Biologics, AbbVie
  • Lisa Zhou, PhD, Senior Scientist, Protein Analytics, AbbVie
  • Eugene Zhukovsky, PhD, CSO, Biomunex Pharmaceuticals
  • Stefan Zielonka, PhD, Group Leader & Principal Scientist, Protein Engineering & Antibody Technologies, Discovery Technologies, Global Research and Development, Merck KGaA
  • Qin Zou, PhD, Group Leader, Analytical Research and Development, Pfizer Inc.
Choose your language
Chinese
Japanese
Korean
English




Premier Sponsors


顯示切換



免費電子郵件通知服務